Effect of buffer species on the complexation of basic drug terfenadine with β-cyclodextrin

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 58, Issue 3-4, 2007, Pages 227-235

  Omari, Mahmoud M A L ^a   Zughul, Mohammad B ^b   Eric D Davies, J ^c   Badwan, Adnan A ^a  

^a JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

cyclodextrin; Buffer type; Hydrophobic effect; Multicomponent complexes; Terfenadine

Indexed keywords

EID: 70349261277     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-006-9147-5     Document Type: Article

References (28)

1. T. Loftsson and M.E. Brewster: J. Pharm. Sci. 85, 1017 (1996).
2. V.J. Stella and R.A. Rajewski: Pharm. Res. 14, 556 (1997).
3. L. Szente, J. Szejtli, M. Vikmon. J. Szeman, E. Fenyvesi, M. Pasini, E. Redenti, and P. Ventura: Proceedings of the 1st World Meeting on Pharm. Biopharm. Pharm. Tech., Chatenary Malabry, France: APG1. p. 579 (1995).
4. E. Redenti, L. Szente, and J. Szejtli: J. Pharm. Sci. 89, 1 (2000).
5. P. Ventura, P. Chiesi, M. Pasini, E. Redenti. J. Szejtli. and M. Vikmon: US Patent 5855916. Chiesi Farmaceutici S.P.A. Co., Italy (1995).
6. A.A. Badwan, A. Abu-Malooh. M. Haddadin. and H. Ibrahim: US Patent 5646131. Arab company for Drug Industries and Medical appliances (ACDIMA), Jordan (1997).
7. M.V. Rekharsky, R.N. Goldberg. F.P. Schwarz, Y.B. Tewari, P.D. Ross. Y. Yamashoji, and Y. Inoue: J. Am. Chem. Soc. 117, 8830 (1995).
8. T. Baekensfeld. B.W. Müller, and K. Kolter: Int. J. Pharm. 74, 85 (1991).
9. B.W. Müller and E. Albers: Int. J. Pharm. 79, 273 (1992).
10. M.T. Esclusa-Diaz. M. Gayo-Otero. M.B. Perez-Marcos, J.L. Vila-Jato, and J.J. Torres-Labandeira: Im. J. Pharm. 142, 183 (1996).
11. Y. Kim, D.A. Oksanen, W. Massefski. J.F. Blake, E.M. Duffy. and B. Chrunyk: J. Pharm. Sci. 87, 1560 (1998).
12. T. Higuchi, and K.A. Connors: In C.N. Reilley (ed.), Adv. Anal. Chem. Instrum. Wiley-Interscience, New York (1965), pp. 117-212.
13. M.B. Zughul and A.A. Badwan: J. Incl. Phenom. 31, 243 (1998).
14. M.M. Al Omari, M.B. Zughul, A.A. Badwan, and J.E.D. Davies: J. Incl. Phenom. 55, 247 (2006).
15. British Pharmacopoeia, British Pharmacopoeia Commission. Market Towers: London; Addendum 1995, (1993)pp. 1613-1614.
16. Astralian National Drug Information Service: Astu. J. Pharm. 67, 1077 (1986).
17. A.E. Lacerda. M.-L. Roy, E.W. Lewis, and D. Rampe: Mol. Pharmacol. 52, 314 (1997).
18. E. Fenyvesi, M. Vikmon, J. Szeman, E. Redenti, M. Delcanale, P. Ventura, and J. Szejtli: J. Incl. Phenom. 33, 339 (1999).
19. L. Liu and Q.-X. Guo: J. Incl. Phenom. 42, 1 (2002).
20. M.M. Al Omari. M.B. Zughul, J.E.D. Davies, and A.A. Badwan: J. Pharm. Biomed. Anal. 41, 857 (2006).
21. M.I. El-Barghouthi, N.A. Masoud, J.K. Al-Kafawein, M.B. Zughul, and A.A. Badwan: J. Incl. Phenom. 53, 15 (2005).
22. A. Baccni, G. Pelizzi. G.M. Sheldrick, G. Amari. M. Delcanale, and E. Redenti: Supramol. Chem. 14, 67 (2002).
23. W. Tong, J.L. Lach. T. Chin, and J.K. Guillory: Pharm. Res. 8, 951 (1991).
24. W. Tong, J.L. Lach. T. Chin, and J.K. Guillory: J. Pharm. Biomed. Anal. 9, 1139 (1991).
25. H. Choi, B. Lee, J. Han, M. Lee, K. Park, C. Yong, J. Rhee, Y. Kim, and C. Kim: Drug Dev. Incl. Pharm. 27, 857 (2001).
26. E. Redenti. M. Pasini, P. Ventura, A. Spisni. and M. Vikmon: J. Incl. Phenom. 15, 281 (1994).
27. E. Redenti, P. Ventura, G. Fronza, A. Selva, S. Rivara, P.V. Plazzi, and M. Mor: J. Pharm. Sci. 88, 599 (1999).
28. M.T. Faucci, F. Melani. and P. Mura: J. Pharm. Biomed. Anal. 23. 25 (2000).